Study of ZIO-201 in Advanced Sarcoma

A Phase IB/IIA Study of the Saftey and Activity of Intravenous Isophosporamide Mustard (ZIO-201) in Patients With Advanced Sarcoma

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00439686

Enrollment

Registered

2007-02-26

Start date

2006-02-28

Completion date

2013-12-31

Last updated

2014-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Sarcoma

Brief summary

The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced sarcoma.

Interventions

DRUGZIO-201

ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Metastatic and /or unresectable disease state after previous standard chemotherapy

Design outcomes

Primary

Measure	Time frame
toxicities	6 months

Secondary

Measure	Time frame
pharmacokinetics	6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026